title: Phase-1/-2 study of pomalidomide in chronic GvHD.
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: I
authors.initials: I
authors.lastname: Pusic
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: M P
authors.initials: MP
authors.lastname: Rettig
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: J F
authors.initials: JF
authors.lastname: DiPersio
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: S
authors.initials: S
authors.lastname: Bauer
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: K
authors.initials: K
authors.lastname: McFarland
authors.affiliation: Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.
authors.forename: R P
authors.initials: RP
authors.lastname: Gale
authors.affiliation: Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: S Z
authors.initials: SZ
authors.lastname: Pavletic
mesh_terms: D000328:Adult; D002908:Chronic Disease; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D013792:Thalidomide; C467566:pomalidomide